Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Endostatin

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1894-2

Definition

Endostatin is a proteolytic fragment derived from the carboxyterminal, non-collagenous domain 1 (NC1) of collagen type XVIII. Endostatin inhibits angiogenesis by blocking endothelial cell proliferation and migration.

Characteristics

Discovery

Endostatin was originally identified in the culture medium of a murine endothelioma cell line by Michael S. O’Reilly et al., from the laboratory of Dr. Judah Folkman. The same group of investigators has also discovered another angiogenesis inhibitor, angiostatin. The search for angiogenesis inhibitors began with the premise that the primary tumor secretes an inhibitor which suppresses the growth of metastatic cells at secondary sites. Biochemical characterization of endostatin showed a molecular mass of 20 KDa containing 184 amino acid residues. Endostatin selectively inhibits endothelial cells and does not affect the growth of non-endothelial cells, including tumor cells. Recombinant mouse endostatin was initially produced in E. coli...

Keywords

Down Syndrome Pancreatic Neuroendocrine Tumor Autosomal Recessive Disease Collagen XVIII Collagenous Domain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Benezra R, Rafii S (2004) Endostatin’s endpoints – deciphering the endostatin antiangiogenic pathway. Cancer Cell 13:205–206CrossRefGoogle Scholar
  2. Folkman J (2006) Antiangiogenesis in cancer therapy – endostatin and its mechanism of action. Exp Cell Res 312:594–607CrossRefPubMedGoogle Scholar
  3. Kalluri R (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3:422–433CrossRefPubMedGoogle Scholar
  4. Marneros AG, Olsen BR (2005) Physiological role of collagen XVIII/endostatin. FASEB J 19:716–728CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of PharmacologyUniversity of MinnesotaMinneapolisUSA